Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HubSpot Inc (HUBS) vs McKesson Corporation (MCK) Price & Performance

HubSpot IncTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

HubSpot Inc vs McKesson Corporation — how do they compare? HubSpot Inc trades at $210.67 (market cap $11.00B), while McKesson Corporation trades at $881.45 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 9.6× HubSpot Inc's market cap, and McKesson Corporation pays a 0.42% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.

HUBSMCK
Market Cap
$11.00B$105.14B
Sector
TechnologyHealth
52-Week High
$522.97$995.69
52-Week Low
$170.39$659.01
Enterprise Value
$9.89B$111.67B
Dividend Yield
0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HubSpot Inc

HubSpot (HUBS) trades at $210.92, down 2.31% on the day, amid a bearish technical signal and recent stock volatility following Q2 2026 results. The company reported strong earnings beats but lowered its customer-growth forecast, contributing to a sharp price decline from previous highs. Revenue growth remains robust at 20% year-over-year, yet high valuation multiples and margin pressures present challenges. Analyst sentiment is predominantly bullish with a $233.93 consensus target, but near-term execution risks and increased AI spending weigh on investor confidence.

The outlook for HUBS hinges on successful execution of its AI-driven strategy amid slower customer acquisition. Investment opportunity lies in its solid revenue growth and market position if it can navigate budget scrutiny and competitive pressures. Key risks include heightened execution risks, potential securities litigation, and the financial impact of strategic shifts, which could limit near-term upside despite long-term transformation potential.

McKesson Corporation

McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.

The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About HubSpot Inc

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

Read more on HUBS

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK